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Lysosomal storage diseases (LSDs) are a group of genetic disorders caused by dysfunction in 
enzymes responsible for the intralysosomal degradation of particular compounds. Given their 
complex nature and the limitations of available therapies, the shift towards the development of 
combination treatments to counteract more effectively the pathological burden of these 
disorders is in the agenda of current research viewing to improve the clinical outcome of LSD 
patients. We consider that treatment strategies relying on RNA interference (RNAi), as well as in 
other RNA-based methodologies, may be feasible and particularly promising if designed in the 
context of a synergistic combinatorial therapeutic approach. We are currently evaluating an 
RNAi-dependent strategy based upon the selective downregulation of genes involved in the 
biosynthesis of glycosaminoglycans (GAGs), the major substrates that accumulate in patients 
suffering from a subset of LSDs called mucopolysaccharidoses (MPSs). Although enzyme 
replacement therapy is already available for some MPSs, it has some serious drawbacks, 
justifying the challenge of developing additional therapies targeting this group of disorders. Our 
goal is to promote an effective reduction of the accumulating substrate, ultimately decreasing or 
delaying MPSs’ symptoms.  
It should be noticed that, even though some substrate reduction therapy (SRT) drugs have 
already been approved (miglustat for GD) or are undergoing clinical trial (genistein and/or 
rhodamine B for MPSs), clinical evaluation of those same drugs has unveiled a few side effects, 
the most well-known being those observed for miglustat, which included osmotic diarrhea and 
weight loss. Nevertheless, chemical drugs aren’t the only way to achieve substrate reduction. 
Ours is fully molecular, drug-free approach, whose major focus relies on the biosynthetic 
pathways giving origin to each one of the GAGs whose degradation is impaired in MPS. Taking 
advantage of the RNAi technology potential, we have designed and assayed specific siRNAs 
targeting genes on those biosynthetic cascades to decrease the levels of production of each 
one of the four substrates. Their efficiency is currently being evaluated in vitro.  
Here we present an overview of the preliminary results of this project and unveil its next steps 
towards a full characterization/evaluation of its potential therapeutic effect. 
